Can BCnU be given before Thiotepa for pcnsl autograft
Reading File
Thiotepa before bcnu
Finding Sources
Searching PubMed
thiotepa BCNU conditioning PCNSL autologous stem cell transplant
Searching the Web
thiotepa before BCNU PCNSL autograft conditioning regimen sequence order
Reading Web Page
https://www.eviq.org.au/cellular-therapies/blood-and-marrow-…
Yes, in the standard BCNU/Thiotepa conditioning regimen for PCNSL autograft, BCNU is given first (Day -6), followed by Thiotepa (Days -5 and -4). So your original question -- "can BCNU be given before Thiotepa?" -- is actually the correct standard sequence.
Standard BCNU/Thiotepa Conditioning Schedule for PCNSL ASCT
| Day | Drug | Dose |
|---|---|---|
| -6 | BCNU (Carmustine) | 400 mg/m² IV over 2 hours |
| -5 | Thiotepa | 5 mg/kg IV over 2-4 hours (dose 1 of 2) |
| -4 | Thiotepa | 5 mg/kg IV over 2-4 hours (dose 2 of 2) |
| 0 | Stem cell infusion | - |
This is consistently reported across the original Illerhaus et al. pilot, the IELSG32 trial arm using this regimen, the Kasenda et al. 2017 phase II study, and current institutional protocols including the Oxford BMT programme (NSSG) and eviQ guidelines.
Why BCNU First?
- Scheduling/logistics: BCNU's 2-hour infusion is given on Day -6, and then a 24-hour post-BCNU hydration flush is run before Thiotepa begins. This gap is important because BCNU can cause pulmonary and hepatic toxicity, and the washout/hydration period helps separate peak toxicities.
- Thiotepa requires intense skin/bladder hydration: Thiotepa is excreted through sweat and urine and causes skin/mucosal toxicity; administering it after BCNU (with pre-hydration already running) helps manage this. Patients require 3L/day fluid intake and frequent showering during Thiotepa days.
- Both are highly lipophilic and CNS-penetrating alkylating agents - the sequence was established empirically in the original pilot and has been maintained in all subsequent studies.
Key Supporting Evidence
- Steffanoni et al. 2023 systematic review (Cancers) confirms BCNU 400 mg/m² day -6, Thiotepa 5 mg/kg days -5 and -4 across all reported studies [PMID: 36672475]
- Arshad et al. 2023 (Bone Marrow Transplant) analysed TT-BCNU outcomes in CIBMTR registry using this same day ordering [PMID: 37563283]
- Akhtar et al. 2024 comparing TBC vs BCNU/Thio in older adults confirms BCNU/Thio superiority in NRM and OS, using identical sequencing [PMID: 39303985]
Bottom line: BCNU before Thiotepa (Day -6 then Days -5/-4) is the standard, validated sequence used globally. The regimen is sometimes called "TT-BCNU" but the actual administration order is always BCNU first.
Is there any rationale that Thiotepa cannot be given before
Searching PubMed
thiotepa carmustine BCNU sequence order conditioning rationale pharmacokinetics
Searching the Web
why thiotepa given after BCNU not before conditioning PCNSL rationale pharmacology sequence
The honest answer here is: there is no strong published pharmacological rationale that strictly prevents Thiotepa from being given before BCNU. The sequence (BCNU day -6 → Thiotepa days -5/-4) is based on historical convention from the original Illerhaus pilot, not on a proven pharmacokinetic or pharmacodynamic superiority of that order.
Here is a breakdown of what is and isn't known:
Why BCNU Comes First - What's Actually Behind It
1. Historical/empirical origin (the main reason)
The sequence was designed by Illerhaus et al. in the early 2000s and simply written into the protocol that way. It was carried forward unchanged into every subsequent study (IELSG32 arm, Kasenda, etc.). There was no sequencing comparison study - the order was set once and replicated. The regimen is sometimes called "TT-BCNU" but the infusion order has always been BCNU first.
2. Practical/logistical reasons that favor BCNU first
- BCNU requires post-infusion hydration for 24 hours (2000 mL saline after infusion). This hydration run naturally bridges into Day -5 when Thiotepa begins - a convenient built-in washout.
- Thiotepa requires very heavy hydration (3L/day) and intensive skin care (frequent showering, urinary catheterisation at some centres). Starting BCNU first means the hydration infrastructure is already running when Thiotepa days begin.
- BCNU has a very short half-life (~70 minutes), so it is essentially cleared before Thiotepa begins the next day. The reverse would also be true pharmacokinetically.
3. No pharmacokinetic argument against reversal
- Thiotepa is rapidly metabolised to TEPA (its active metabolite, t½ ~3-4 hours for thiotepa, ~21 hours for TEPA). By the time BCNU would be given 24 hours later, systemic thiotepa levels are minimal.
- Neither drug is a known inducer/inhibitor of the other's metabolism - thiotepa is metabolised by CYP2B6/CYP3A4; BCNU is primarily non-enzymatic (spontaneous hydrolysis/alkylation). No clinically significant PK interaction exists regardless of order.
- There is no evidence of synergistic DNA damage requiring a specific sequence (unlike, say, cisplatin before paclitaxel where sequence affects tubulin binding).
4. Overlapping toxicity concern - theoretical argument for BCNU first
Both drugs cause pulmonary toxicity (BCNU - classic pneumonitis; Thiotepa - less commonly). One could argue giving BCNU first, then Thiotepa, staggers the pulmonary insult slightly. But this is a theoretical concern, not studied.
Similarly, hepatotoxicity (particularly sinusoidal obstruction syndrome) is a concern with Thiotepa at high doses. Giving BCNU first and then Thiotepa closer to stem cell infusion (Day -4 = 4 days before engraftment) may theoretically allow BCNU-related hepatic stress to begin resolving before Thiotepa's hepatic load peaks - but again, this is speculative.
Bottom Line
| Consideration | Verdict |
|---|---|
| Published evidence against Thiotepa first | None |
| Pharmacokinetic interaction requiring BCNU first | None demonstrated |
| Reason for current sequence | Historical convention from original pilot |
| Practical hydration logistics | Favor BCNU first (minor) |
| Theoretical toxicity staggering | Marginally favors BCNU first |
| Has Thiotepa-first sequence ever been tested? | No published data |
The sequence has never been formally challenged or compared in a clinical study. If a centre were to give Thiotepa before BCNU for a logistical reason (e.g., drug supply), there is no known pharmacological reason this would be harmful - but it would represent a deviation from the validated protocol. Any such deviation in a transplant conditioning setting should go through institutional pharmacy and transplant committee review given the high-dose, myeloablative context.
This is a shared conversation. Sign in to Orris to start your own chat.